Headache and Migraine

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 11, 2022.

Patients with chronic migraine on 60-mg once-daily and 30-mg twice-daily atogepant demonstrated reductions of 6.88 and 7.46 monthly migraine days, respectively, over a 12-week period.

Data from the 24-week, multicenter LibraTN trial are expected to be reported in the first half of 2024.

More than half of the patients with episodic migraine considered the likelihood of migraine on day 1 postdosing to be as important as the reduction in migraines in the days to follow.

Factors such as fear of negative consequences, attention and anticipation, and fear-avoidances were identified using the newly developed Fear of Attacks in Migraine Inventory questionnaire, which may have use in clinical settings.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is nutrition in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 4, 2022.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 25, 2022.

The assistant director of the Allegheny Headache Center provided context on a recently created headache registry and the need to prioritize treatment outcomes that matter to patients.

When adding Nerivio’s Guided Imagery, Education and Relaxation, or GIER, behavioral intervention, 79.4% of responders achieved consistent pain relief compared with 56.8% of those treated solely with the REN device.

The assistant director of the Allegheny Headache Center provided insight on how the center utilizes its headache registry to construct treatment plans, along with identifying questions that still need answers. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 18, 2022.

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

The assistant director of the Allegheny Headache Center explained the origins of the recently launched headache registry, which keeps data about patients’ responses to medications. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive®.

The phase 4 study will evaluate the efficacy and safety of once-monthly injectable galcanezumab compared with every-other-day rimegepant taken orally.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 11, 2022.

The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]

This was the first study to demonstrate a preventive treatment signal in migraine when an approved oral CGRP receptor antagonist is dosed as needed for the acute treatment of migraine.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.

The assistant clinical professor at Vanderbilt University School of Medicine discussed ways of incorporating and encouraging women physicians to enter the neurology specialty. [WATCH TIME: 4 minutes]

Most child neurologist respondents were generally early in their career, had diverse subspeciality training, and tended to work at large, resource-rich centers capable of multimodal neuromonitoring.

Although research illustrates the persistence of inequities between women and men in neurology, 3 women leaders shared encouraging thoughts and experiences highlighting the progress made in recent years.